IN SILICO EPIOTOPE PREDICTION AND VP1 MODELLING FOR FOOT-AND-MOUTH SEROTYPE SAT 2 FOR VACCINE DESIGN IN EAST AFRICA

Jean Claude Udahemuka^{1,2}, Lunayo Accadius¹, George Obiero¹, Gabriel Aboge³, Phiyani Lebea⁴

¹Centre for Biotechnology and Bioinformatics, University of Nairobi, P.O. Box 30197, Nairobi, Kenya.

²Department of Veterinary Medicine, University of Rwanda, P.O. Box 57, Nyagatare, Rwanda.

³Department of Public Health, Pharmacology and Toxicology, University of Nairobi, P.O. Box 29053, Nairobi, Kenya.

⁴TokaBio (Pty), Ltd, Pretoria, South Africa

Abstract

Foot and Mouth Disease Virus has seven distinct, geographically localized, serotypes and a vaccination targeting one serotype does not confer immunity against another serotype. The use of inactivated vaccines is not safe and confers an immunity with a relatively shorter time. Using the VP1 sequences isolated in East Africa, we have predicted epitopes able to induce humoral and cell-mediated immunity in cattle. The Wu-Kabat variability index calculated in this study reflects the variable, including the known GH loop, and conserved regions, with the latter being good candidates for region-tailored vaccine design. Furthermore, we modelled the identified epitopes on a 3D model (PDB ID:5aca) to represent the epitopes structurally. This study can be used for *in vitro* and *in vivo* experiments.

Keywords:

FMDV, SAT2, Epitope prediction, Vaccine design, VP1 variability

1. Introduction

Foot-and-Mouth Disease (FMD) is an infectious disease caused by the Foot-and-Mouth Disease Virus (FMDV) of the family of picornaviridae (1). FMD is endemic in Africa and South-Eastern Asia with sporadic outbreaks in other countries (2–4). Seven distinct serotypes have been identified and geographically localized with seven pools (4) and SAT2 has been responsible for several outbreaks in Eastern Rwanda (5). Vaccination against one serotype does not confer immunity against other serotypes (6). Therefore, high potency multivalent vaccines have been developed (7) and a continuous study of molecular epidemiology at the regional and national level is of paramount importance to have regional-tailored vaccines. Poor understanding of circulating strains leads to limited vaccine matching and vaccine failure (8). The peptide-based vaccines paradigm has been proposed as an alternative to the currently used inactivated vaccines (9–11). This study is exploring the variability of FMDV SAT2 VP1 protein in EAC and *in silico* predicting highly potential epitopes to be targeted for epitope-based vaccines. Furthermore, we have complemented the prediction with a three-dimension (3D) presentation of the FMDV capsid using a close model available on the Protein Database Bank platform. The epitopes predicted in this study can be used to guide in choosing strains to include in vaccines or designing a peptide-based vaccine.

2. Materials and Methods

2.1. Selection of FMDV SAT2 VP1 sequences

In this study's analysis, we analyzed the sequences from the field samples we collected and other sequences available online. For the latter, we searched online on three repositories namely; NCBI, EBI and DDBJ, using the following criteria, sequences identified as SAT2, sequences of VP1, sequence length between 212 and 216 amino acids, sequences of samples collected in the FMD pool IV, Great lakes region cluster countries (Burundi, Kenya, Rwanda, Tanzania and Uganda) together with DRC and samples collected after the year 2010. The latter criteria were not followed for samples collected in

Burundi, DRC and Rwanda because of the scarcity of available sequences. The selected sequences following the above criteria are available online at [10.6084/m9.figshare.14979594](https://doi.org/10.6084/m9.figshare.14979594).

2.2.VP1 sequence variability in Great Lakes cluster of FMDV pool IV

We used a Python 3 notebook to create a dictionary that can transcribe the bases of the raw field sequences into amino acids. The EBI ClustalW was used to run a multiple sequence alignment to obtain a consensus sequence. The VP1 consensus sequence was used to search for a three-dimensional (3D) model of the structure that is more likely to be found in the region of East Africa. The protein variability server (PVS) tool was used to calculate and represent a Wu-Kabat coefficient for variability following the formula below:

$$\text{Variability} = N * k / n \quad (12,13)$$

With N being the number of sequences in the alignment, k is the number of different amino acids at each position and n is the number of times for the most common amino acids per position. The Wu-Kabat coefficient was used to compare the variability of the predicted epitopes.

2.3.Epitope prediction and 3D modelling

The PVS was used to run a sequence alignment and analyze the variability of the selected sequences. To evaluate the positional variability of amino acids, we used the Wu-Kabat coefficient. SWISS-MODEL was used to select the fittest online available model and run its evaluation. The stereochemistry of the structure was evaluated using the Ramachandran plot to study the acceptability of the model.

We used the BepiPred-2.0 server to predict sequential B-cell epitopes with an epitope threshold set at 0.5. Likewise, the MHC-I binding predictions were made on 7/28/2021 using the IEDB analysis resource NetMHCpan (ver. 4.1) tool (14). For the protein digestion, we set the IEDB recommended 2020.09 (NetMHCpan EL 4.1) settings and digesting the protein in peptides ranging from 8 to 14-mers. The Bovine Leukocyte Antigen (BoLA) alleles available on the platform were all selected as ligands with default parameters. The peptides scoring more than 0.5 were considered for further analysis. The

74 PyMol 2.5 (15) was used for the visualization of the selected model and to map the identified epitopes
75 on the FMDV VP1 in 3-D presentation.

76

3. Results

3.1.VP1 sequence variability in Great Lakes cluster of FMDV pool IV

Figure 1: Similarity alignment of putative VP1 proteins of Foot and Mouth Disease serotype SAT 2 in East Africa

We used Python 3 to transcribe field sequence bases into amino acids and aligned field sequences with retrieved sequences. The VP1 sequences alignment using the CLC Main Work Bench 21.0.4 is presented in figure 1. The protein variability plot was obtained using the Protein Variability Server (PVS) by calculating the Wu-Kabat coefficient Figure 2. We identified at least two regions (residue 45-60 and residue 138-140) that are highly variable across the selected sequences and position 58 being the most variable.

Figure 2: Wu-Kabat plot displaying the variability of VP1 proteins of FMDV SAT2 isolates from East Africa. The black rectangles highlight variable motifs with at least 3 variable positions. The plot was constructed using the Protein Variability Server (13).

The residue 58-60 and at positions 85, 108 were variable in a way that Nyagatare isolate is identical to isolates QDC11914, QDC11915 and QDC11965 isolated in cattle (*Bos taurus*) in Kenya at the livestock-wildlife interface between 214 and 2016. Likewise, at the same positions, the Gatsibo isolate was identical to AJI77552 (cattle, Kenya, 2011), AJI77553 (cattle, Kenya, 2012), AJM93656 (cattle, Uganda, 2013), AXI68799 (cattle, Tanzania, 2011), AXI68832 (cattle, Tanzania, 2012) and QBY97746 (cattle, Tanzania, 2016). The below phylogenetic representation (Figure 3) illustrates that at least FMD SAT2 viruses circulating in the region can be considered as two bigger branches.

Figure 3: Phylogeny of FMD SAT2 isolates circulating in East Africa

3.2.Epitope prediction and 3D modelling

The multiple sequence alignment of the 11 FMD VP1 sequences was obtained using the European Bioinformatics Institute (EBI) online platform. Using the EBI's EMBOSS program, the resulting consensus sequence (TTSAGEGADVVTDPSTHGGSVVEKRRMHTDVAFVLDRFTHVHTGKTTFNVDLMD TKQHALVGALLRASTYYFCLEIACVGDHTRVFWQPNGAPRTTQLGDNPMVFPHN GVTRFAIPYTAPHRLLATVYNGECKYTERVSAIRGDRAVLAAKYADTRHTLPSTFNF GHVTADQPVDVYYRMKRAELYCPRLLPAYQHNGRDRFDAPIGVEKQLC) was obtained. We searched for a model close to the consensus sequence with available structures in the protein data bank using the SWISS-MODEL, the model with PDB id: 5ACA was selected. The modelled structure had a global QMEANDisCo of (0.77 ± 0.06) with a molprobtity score of 1.50 and a Ramachandran favoured score of 91.35% A Ramachandran plot (Figure 4) showed that the structure can be accepted and considered for 3D structure presentation.

Figure 4: A Ramachandran plot for the selected 3D structure model showing the position of different amino acids

3.2.1. B-cell epitopes

The mapping of epitopes in Figure 5 was obtained with the consensus sequence to predict the sequential B-cell epitopes DTU online platform (BepiPred-2.0) (16) and Table 1 describes the predicted peptides with their positions.

The 5ACA VP1 based model was selected for a 3D presentation and the consensus sequence aligned to the 5ACA VP1 sequence to study the variability results are presented in Table 1 with the predicted B-cell epitopes.

Figure 5: Representation of sequential B-cell epitopes prediction

Table 1: Predicted linear epitopes

No	Start	End	Peptide	Number of residues	Score
1	198	213	PGYDHADRDRFDSPIG	16	0.816
2	1	30	TTSSGEGADVTTDPSTHGGAVTEKKRVHT	30	0.798
3	129	168	RYNGECKYTQKLPSTF	16	0.67
4	92	114	NGAPRTTTLRDNPMVFSHNNVTR	23	0.64
5	81	88	LGEHERVW	8	0.614
6	175	178	ADKP	4	0.612
7	121	125	APHRL	5	0.539

Furthermore, discontinuous B-cell epitopes were determined using the IEDB online platform by setting the threshold at 0.5. The resulting eight peptides are represented in Table 2:

Table 2: Predicted Discontinuous Epitopes

No	Residues	Number of residues	Score
1	T136, T137, Q138	3	0.929
2	T1, T2, S3, S4, G5, E6, G7, A8, D9, V10, V11, T12, T13, D14, P15, S16, T17, H18, G19, G20, A21, V22, T23, E24	24	0.854
3	P198, G199, Y200, D201, H202, A203, D204, R205, D206, R207, F208, D209, S210, P211, I212, G213	16	0.816
4	Y130, N131, G132, E133, C134, K135	6	0.806
5	T44, N45, T47, L81, G82, E83, H84, E85, R86, W88, T97, T98, T99, L100, R101, D102, N103, P104, M105, V106, F107, S108, H109, N110, N111, V112, A175, D176, K177, P178	30	0.645
6	P91, N92, G93, A94, P95, R96	6	0.562

Using the PyMol software, we loaded the model (PDB ID:5aca) and mapped both linear and discontinuous epitopes. For visibility, we only present epitopes scoring ≥ 8 .

136

137 *Figure 6: Humoral epitope prediction on the FMDV SAT2 VP1 consensus sequence isolated in East*
138 *Africa. Fig. 6.A represents linear epitopes with residue 198-213 (firebrick) and residue 1-30 (blue)*
139 *while Fig.6.B represents discontinuous epitopes with residue 136-138 (blue), residue 1-24 (firebrick),*
140 *residue 198-213 (orange) and residue 130-135 (yellow).*

141 3.2.2. T-cell epitopes

142 The following alleles were selected (BoLA-1:00901, BoLA-2:00501, BoLA-3:00101, BoLA-
143 4:02401, BoLA-5:00301, BoLA-6:01301, BoLA-amani.1, BoLA-AW10, BoLA-D18.4,
144 BoLA-gb1.7, BoLA-HD6, BoLA-JSP.1, BoLA-T2a, BoLA-T2b, BoLA-T2c, BoLA-T5,
145 BoLA-T7) to analyze their affinity to different peptide sizes ranging from 8 to 12 amino acids.

146 By considering the threshold of score ≥ 0.5 , we remained with 42 potential epitopes (Table 2).
147 Among the latter, at least ten pairs (BoLA-HD6*KQHALVGAL, BoLA-
148 6:01301*KQHALVGAL, BoLA-T2c*DLMDTKQHAL, BoLA-HD6*KQHALVGALL,
149 BoLA-6:01301*KQHALVGALL, BoLA-T2c*LMDTKQHAL, BoLA-T2c*IPYTAPHRL
150 and BoLA-amani.1*HTLPSTFNF) scored more than 0.8. Furthermore, certain sequence
151 regions contained peptides that could be considered to induce both B-cell and T-cell immune
152 responses, among them two pairs (BoLA-1:00901*SVVEKRRMH and BoLA-
153 amani.1*HTLPSTFNF) had scored 0.798 and 0.810 consecutively. The epitope in the second

couple (res 156-166) is shown to be very variable which can lead to vaccine failure and is located in a region able to induce both B-cell and T-cell immunity.

Table 3: Different combinations of BoLA alleles with several peptides with their scores

Allele	Start	End	Length	Peptide	Score
BoLA-HD6	57	65	9	KQHALVGAL	0.944025
BoLA-6:01301	57	65	9	KQHALVGAL	0.944025
BoLA-T2c	52	61	10	DLMDTKQHAL	0.926703
BoLA-HD6	57	66	10	KQHALVGALL	0.889007
BoLA-6:01301	57	66	10	KQHALVGALL	0.889007
BoLA-T2c	186	194	9	ELYCPRPLL	0.88009
BoLA-1:00901	35	43	9	VLDRFTHVH	0.83814
BoLA-T2c	53	61	9	LMDTKQHAL	0.831496
BoLA-T2c	117	125	9	IPYTAPHRL	0.812674
BoLA-amani.1	159	167	9	HTLPSTFNF	0.810081
BoLA-1:00901	21	29	9	SVVEKRRMH	0.798875
BoLA-D18.4	152	161	10	AKYADTRHTL	0.780555
BoLA-D18.4	197	205	9	YQHNGRDRF	0.74142
BoLA-D18.4	57	65	9	KQHALVGAL	0.729915
BoLA-1:00901	10	18	9	VVTDPSTH	0.724788
BoLA-2:00501	117	125	9	IPYTAPHRL	0.705937
BoLA-T2a	16	25	10	STHGGSVVEK	0.672179
BoLA-1:00901	151	159	9	AAKYADTRH	0.655482
BoLA-T2c	41	49	9	HVHTGKTTF	0.640734
BoLA-1:00901	115	123	9	FAIPYTAPH	0.632319
BoLA-1:00901	34	43	10	FVLDRFTHVH	0.628662
BoLA-HD6	27	36	10	RMHTDVAFVL	0.617185
BoLA-6:01301	27	36	10	RMHTDVAFVL	0.617185
BoLA-T2a	47	57	11	TTFNVDLMDTK	0.606006
BoLA-T2c	34	42	9	FVLDRFTHV	0.60583
BoLA-T2c	92	100	9	NGAPRTTQL	0.596903
BoLA-D18.4	180	188	9	YRMKRAELY	0.583383
BoLA-1:00901	128	136	9	TVYNGECKY	0.568695

BoLA-5:00301	57	65	9	KQHALVGAL	0.555735
BoLA-D18.4	157	165	9	TRHTLPSTF	0.547177
BoLA-HD6	89	100	12	WQPNGAPRTTQL	0.533673
BoLA-6:01301	89	100	12	WQPNGAPRTTQL	0.533673
BoLA-1:00901	34	41	8	FVLDRFTH	0.532174
BoLA-1:00901	64	72	9	ALLRASTYY	0.529423
BoLA-D18.4	26	34	9	RRMHTDVAF	0.526979
BoLA-HD6	184	194	11	RAELYCPRPLL	0.523536
BoLA-6:01301	184	194	11	RAELYCPRPLL	0.523536
BoLA-5:00301	153	161	9	KYADTRHTL	0.523059
BoLA-T2c	174	182	9	QPVDVYYRM	0.513212
BoLA-T2c	65	73	9	LLRASTYYF	0.506616
BoLA-T2c	99	107	9	QLGDNPMVF	0.502826
BoLA-2:00501	121	129	9	APHRLLATV	0.502133

157

158 Furthermore, we joined several epitopes by removing the noise and we adopted the GPGPG
159 spacer as previously used (17). However, some epitopes overlapped and were combined as
160 continuous residue. Therefore, the resulting multiepitope peptide is
161 ¹⁰VVTTPSTHGGSVVEKRRMHTDVAFLDRFTHVHTGKTTFNVDLMDTKQHALVG
162 ALLRASTYYF⁷³**GPGPG**⁸⁹WQPNGAPRTTQLGDNPMVF¹⁰⁷**GPGPG**¹¹⁵FAIPYTAPHRLLA
163 TVYNGECKY¹³⁶**GPGPG**¹⁵¹AAKYADTRHTLPSTFNF¹⁶⁷. Finally, we mapped epitopes
164 scoring ≥ 8 to the 3D model (figure 7).

165

166 *Figure 7: Three-dimensional mapping on the selected model (PDB ID: 5aca) of the predicted MHC I*
 167 *T-cell epitopes scoring ≥ 8 . Epitope residues are highlighted as follows: residue 21-29 (firebrick),*
 168 *residue 35-43 (blue), residue 52-66 (yellow), residue 117-125 (magenta), residue 159-167 (orange) and*
 169 *residue 186-194 (cyan).*

170

171 4. Discussion

172 The present study proposes peptides with a higher probability to induce B and T cell immune
 173 responses in cattle and therefore can be considered as good candidates for vaccine design.
 174 Using the Wu-Kabat variability index available at the protein variability server, the variability
 175 plot we obtained with SAT2 was less variable compared to the Asia1 serotype variability

obtained by Sultana *et al.*(18). This study emphasizes a regional intratypic variability found at least in three positions. Sahle *et al.*(19) described variable sites (positions 46-51, 109-114, 134-147 and 152-157) in SAT 1 that are approximately equivalent to the ones observed with this study's SAT 2 sequences (positions 45-50, 107-111, 135-141 and 151-160) with the RGD site (149-151) and C- terminus (202-217) being relatively conserved for both serotypes.

Though *in silico* prediction of epitopes is very important, it has to be coupled with thermal stabilization of the identified epitopes because of the thermal lability of SAT serotypes (20). The BoLA system showed to have an affinity to surface-exposed peptides of the VP1 with the BoLA-HD6 allele to have the highest affinity while Agrawal *et al.* found that BoLA-T7 had the highest percentile rank towards PPRV peptides (21). The identified epitopes can be used to design a polytope-based plasmid DNA vaccine using linkers and adjuvant (17,22) that can be tested *in vitro* and *in vivo*.

5. Conclusion

Experimentations using the predicted peptides can lead to region-tailored DNA vaccines development. Special focus should be put on residues that showed low variability and to induce B-cell immunity and high affinity to BoLA alleles for *in vitro* and *in vivo* testing. A deeper understanding of molecular epidemiology in East Africa can improve the effectiveness of the predicted epitopes. We, therefore, recommend more fieldwork especially in countries where little is known in terms of circulating strains. In the future, advanced AI-based tools to predict protein folding, such as Alpha Fold 2, can be used for epitope mapping on 3D structures.

References

1. Stanway G, Brown F, Christian PD, Hovi T, Hyypiä T, King AMQ, et al. Taxonomy of the Picornaviridae : Species Designations and Three New Genera. Abstracts of the XIth Meeting of

the European Study Group on Molecular Biology of Picornaviruses. [Internet]. 2000. Available from: https://www.picornastudygroup.com/posters/europic_2000.pdf

2. Jamal SM, Belsham GJ. Foot-and-mouth disease: past, present and future. *Vet Res.* 2013;44(116):1–14.

3. Sumption K, Rweyemamu M, Wint W. Incidence and Distribution of Foot-and-Mouth Disease in Asia, Africa and South America; Combining Expert Opinion, Official Disease Information and Livestock Populations to Assist Risk Assessment. *Transbound Emerg Dis* [Internet]. 2008 Jun 28;55(1):5–13. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/j.1865-1682.2007.01017.x>

4. Brito BP, Rodriguez LL, Hammond JM, Pinto J, Perez AM. Review of the Global Distribution of Foot-and-Mouth Disease Virus from 2007 to 2014. *Transbound Emerg Dis* [Internet]. 2017 Apr;64(2):316–32. Available from: <https://onlinelibrary.wiley.com/doi/10.1111/tbed.12373>

5. Udahemuka JC, Aboge GO, Obiero GO, Lebea PJ, Onono JO, Paone M. Risk factors for the incursion, spread and persistence of the foot and mouth disease virus in Eastern Rwanda. *BMC Vet Res.* 2020 Dec;16(1):387.

6. Rowlands DJ, Clarke BE, Carroll AR, Brown F, Nicholson BH, Bittle JL, et al. Chemical basis of antigenic variation in foot-and-mouth disease virus. *Nature* [Internet]. 1983 Dec;306(5944):694–7. Available from: <http://www.nature.com/articles/306694a0>

7. Waters R, Ludi AB, Fowler VL, Wilsden G, Browning C, Gubbins S, et al. Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage. *Vol. 36, Vaccine.* 2018. p. 1901–7.

8. FAO/EuFMD. EuFMD P II: European Neighborhood/ Report on Significant FAST disease events and information [Internet]. Rome; 2020. Available from: <https://rr-middleeast.oie.int/wp->

224 content/uploads/2021/01/eufmd_pii_report_on_significant_fast_disease_events_and_infor
225 mation_october_december_2020.pdf

226 9. Wang CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, et al. Effective synthetic peptide
227 vaccine for foot-and-mouth disease in swine. *Vaccine* [Internet]. 2002 Jun;20(19–20):2603–
228 10. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0264410X02001482>

229 10. Forner M, Cañas-Arranz R, Defaus S, de León P, Rodríguez-Pulido M, Ganges L, et al. Peptide-
230 Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health. *Vaccines*
231 [Internet]. 2021 May 8;9(5):477. Available from: <https://www.mdpi.com/2076-393X/9/5/477>

232 11. Defaus S, Forner M, Cañas-Arranz R, de León P, Bustos MJ, Rodríguez-Pulido M, et al.
233 Designing Functionally Versatile, Highly Immunogenic Peptide-Based Multiepitopic Vaccines
234 against Foot-and-Mouth Disease Virus. *Vaccines* [Internet]. 2020 Jul 22;8(3):406. Available
235 from: <https://www.mdpi.com/2076-393X/8/3/406>

236 12. Kabat EA, Wu TT, Bilofsky H. Unusual distributions of amino acids in complementarity
237 determining (hypervariable) segments of heavy and light chains of immunoglobulins and their
238 possible roles in specificity of antibody-combining sites. *J Biol Chem*. 1977;252(19):6609–16.

239 13. Garcia-Boronat M, Diez-Rivero CM, Reinherz EL, Reche PA. PVS: a web server for protein
240 sequence variability analysis tuned to facilitate conserved epitope discovery. *Nucleic Acids*
241 *Res* [Internet]. 2008 May 19;36(Web Server):W35–41. Available from:
242 <https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkn211>

243 14. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0:
244 improved predictions of MHC antigen presentation by concurrent motif deconvolution and
245 integration of MS MHC eluted ligand data. *Nucleic Acids Res* [Internet]. 2020 Jul
246 2;48(W1):W449–54. Available from:
247 <https://academic.oup.com/nar/article/48/W1/W449/5837056>

- 248 15. Schrödinger L. The PyMOL Molecular Graphics System, Version 2.5. 2021.
- 249 16. Galgonek J, Vymětal J, Jakubec D, Vondrášek J. Amino Acid Interaction (INTAA) web server.
250 Nucleic Acids Res [Internet]. 2017 Jul 3 [cited 2021 Aug 6];45(W1):W388–92. Available from:
251 <http://www.cbs.dtu.dk/services/BepiPred/>
- 252 17. Raza S, Siddique K, Rabbani M, Yaqub T, Anjum AA, Ibrahim M, et al. In silico analysis of four
253 structural proteins of aphthovirus serotypes revealed significant B and T cell epitopes. Microb
254 Pathog [Internet]. 2019;128(January):254–62. Available from:
255 <https://doi.org/10.1016/j.micpath.2019.01.007>
- 256 18. Sultana M, Alam S, Rahmman MZ, Hossain M, Amin R. Antigenic heterogeneity of capsid
257 protein VP1 in foot-and-mouth disease virus (FMDV) serotype Asia1. Adv Appl Bioinforma
258 Chem [Internet]. 2013 Aug;6(1):37. Available from: [http://www.dovepress.com/antigenic-](http://www.dovepress.com/antigenic-heterogeneity-of-capsid-protein-vp1-in-foot-and-mouth-diseas-peer-reviewed-article-AABC)
259 [heterogeneity-of-capsid-protein-vp1-in-foot-and-mouth-diseas-peer-reviewed-article-AABC](http://www.dovepress.com/antigenic-heterogeneity-of-capsid-protein-vp1-in-foot-and-mouth-diseas-peer-reviewed-article-AABC)
- 260 19. Sahle M, Dwarka RM, Venter EH, Vosloo W. Comparison of SAT-1 foot-and-mouth disease
261 virus isolates obtained from East Africa between 1971 and 2000 with viruses from the rest of
262 sub-Saharan Africa. Arch Virol [Internet]. 2007 Apr 3;152(4):797–804. Available from:
263 <http://link.springer.com/10.1007/s00705-006-0893-x>
- 264 20. Doel TR, Baccarini PJ. Thermal stability of foot-and-mouth disease virus. Arch Virol [Internet].
265 1981 Mar;70(1):21–32. Available from: <http://link.springer.com/10.1007/BF01320790>
- 266 21. Agrawal A, Gupta R, Gattani A, Patel SK, Khan MH, Singh P. Novel T Cell Epitope Designing
267 from PPRV HN Protein for Peptide based Subunit Vaccine: An Immune Informatics Approach.
268 Int J Curr Microbiol Appl Sci [Internet]. 2020 Mar 20;9(3):2432–9. Available from:
269 <https://www.ijcmas.com/abstractview.php?ID=16563&vol=9-3-2020&SNo=278>
- 270 22. Michel-Todó L, Bigey P, Reche PA, Pinazo M-J, Gascón J, Alonso-Padilla J. Design of an
271 Epitope-Based Vaccine Ensemble for Animal Trypanosomiasis by Computational Methods.

272 Vaccines [Internet]. 2020 Mar 16;8(1):130. Available from: <https://www.mdpi.com/2076->
273 393X/8/1/130
274

List of figures.

Figure 1: Similarity alignment of putative VP1 proteins of Foot and Mouth Disease serotype SAT 2 in East Africa

Figure 2: Wu-Kabat plot displaying the variability of VP1 proteins of FMDV SAT2 isolates from East Africa. The black rectangles highlight variable motifs with at least 3 variable positions. The plot was constructed using the Protein Variability Server

Figure 3: Phylogeny of FMD SAT2 isolates circulating in East Africa

Figure 4: A Ramachandran plot for the selected 3D structure model showing the position of different amino acids

Name	Sequence Markup
Sequence	Epitopes :EEEEEEEEEEEEEEEEEEEE.....EEEEEEEEEEEE.....EEEEEEEE..... Predictions: TTSAGEGADVTTDPSTHGGSVVEKRRMHTDVAFLDRFTHVHTGKTTFNVDLMDTKQHALVGALLRASTYYFCDLEIACVGDHTRVFQPNGAPRTTQLGDNPMVFPHNGV 1-----10-----20-----30-----40-----50-----60-----70-----80-----90-----100-----110 EEEEEEEEEEEE.....EEEEEEEE.....EEEEEEEEEEEE..... INGVTRFAIPYTAPHRLLATVYNGECKYTERVSAIRGDRAVLAAKYADTRHTLPSTFNFHGVTDQPPVDVYYRMKRAELYCPRPLLPAHQHNGRDRFDAPIGVEKQ 110-----120-----130-----140-----150-----160-----170-----180-----190-----200-----210--

Figure 5: Representation of sequential B-cell epitopes prediction

Figure 6: Humoral epitope prediction on the FMDV SAT2 VP1 consensus sequence isolated in East Africa. Fig. 6.A represents linear epitopes with residue 198-213 (firebrick) and residue 1-30 (blue) while Fig6.B represents discontinuous epitopes with residue 136-138

Figure 7: Three-dimensional mapping on the selected model (PDB ID: 5aca) of the predicted MHC I T-cell epitopes scoring ≥ 8 . Epitope residues are highlighted as follows: residue 21-29 (firebrick), residue 35-43 (blue), residue 52-66 (yellow), residue 117-125 (mag)